Ferguson Wellman Capital Management Inc. Trims Position in Humana Inc. (NYSE:HUM)

Ferguson Wellman Capital Management Inc. trimmed its position in shares of Humana Inc. (NYSE:HUM) by 0.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,945 shares of the insurance provider’s stock after selling 40 shares during the period. Ferguson Wellman Capital Management Inc.’s holdings in Humana were worth $3,467,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Swedbank AB raised its holdings in Humana by 3.0% during the third quarter. Swedbank AB now owns 105,976 shares of the insurance provider’s stock valued at $33,567,000 after acquiring an additional 3,085 shares during the period. Heritage Oak Wealth Advisors LLC bought a new stake in Humana during the 2nd quarter valued at approximately $3,456,000. APG Asset Management US Inc. lifted its holdings in Humana by 3.0% in the 2nd quarter. APG Asset Management US Inc. now owns 67,669 shares of the insurance provider’s stock worth $25,274,000 after purchasing an additional 1,955 shares in the last quarter. Sei Investments Co. boosted its stake in Humana by 0.4% in the 1st quarter. Sei Investments Co. now owns 61,897 shares of the insurance provider’s stock worth $21,462,000 after purchasing an additional 264 shares during the period. Finally, Cetera Advisors LLC raised its position in shares of Humana by 472.1% during the first quarter. Cetera Advisors LLC now owns 10,098 shares of the insurance provider’s stock valued at $3,501,000 after buying an additional 8,333 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Trading Up 0.3 %

Shares of HUM traded up $0.80 during trading hours on Friday, reaching $267.14. 4,660,847 shares of the company traded hands, compared to its average volume of 1,846,211. The stock’s fifty day moving average price is $315.89 and its 200 day moving average price is $338.27. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. The firm has a market cap of $32.19 billion, a price-to-earnings ratio of 16.64, a PEG ratio of 1.91 and a beta of 0.50. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $527.18.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.89 by $1.07. The company had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the company earned $8.94 EPS. Sell-side analysts forecast that Humana Inc. will post 16.06 earnings per share for the current year.

Humana Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.33%. The ex-dividend date is Monday, September 30th. Humana’s payout ratio is 22.04%.

Analyst Ratings Changes

Several research firms recently weighed in on HUM. Morgan Stanley began coverage on shares of Humana in a research note on Monday, June 24th. They set an “equal weight” rating and a $374.00 target price for the company. Bank of America cut Humana from a “neutral” rating to an “underperform” rating and reduced their target price for the stock from $376.00 to $247.00 in a report on Wednesday, October 2nd. UBS Group dropped their price target on Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a research note on Friday, October 4th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $395.00 price objective on shares of Humana in a research note on Tuesday, October 1st. Finally, Leerink Partners downgraded Humana from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $400.00 to $250.00 in a research report on Wednesday, October 2nd. One equities research analyst has rated the stock with a sell rating, nineteen have given a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $315.33.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.